Cargando…
Profile of nelarabine: use in the treatment of T-cell acute lymphoblastic leukemia
Nelarabine is the prodrug of 9-β-arabinofuranosylguanine (ara-G) and is therapeutically classified as a purine nucleoside analog. Nelarabine is converted to ara-G by adenosine deaminase and transported into cells by a nucleoside transporter. Ara-G is subsequently phosphorylated to ara-G triphosphate...
Autores principales: | Reilly, Kelly M, Kisor, David F |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2886323/ https://www.ncbi.nlm.nih.gov/pubmed/20616909 |
Ejemplares similares
-
Nelarabine in the Treatment of Refractory T-Cell Malignancies
por: Roecker, Andrew M., et al.
Publicado: (2010) -
Role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma
por: Cooper, Todd M
Publicado: (2007) -
Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma/leukemia
por: Shimony, Shai, et al.
Publicado: (2022) -
Nelarabine-induced rhabdomyolysis in a patient with T-cell acute lymphoblastic leukemia: a case report
por: Utsumi, Akari, et al.
Publicado: (2022) -
MRI findings of nelarabine‐related rhabdomyolysis in a patient with refractory T‐cell acute lymphoblastic leukemia
por: Mukai, Daiki, et al.
Publicado: (2023)